Prevymis (letermovir) is used for the prevention of cytomegalovirus (CMV) infection in patients who have received an allogeneic stem-cell transplant (from a matching donor). Cytomegalovirus is a potentially serious viral infection that is more common in patients who are immune-suppressed, such as AIDS patients, people with cancer, people receiving organ or bone marrow transplants, and newborn babies of women infected with CMV during pregnancy. The FDA approved Merck's Prevymis in November 2017.
Subscribe to receive email notifications whenever new articles are published.
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Data sources include Micromedex® (updated Oct 1st, 2018), Cerner Multum™ (updated Oct 2nd, 2018), Wolters Kluwer™ (updated Oct 2nd, 2018) and others. To view content sources and attributions, please refer to our editorial policy.